PRTA News and Press, Prothena Corporation plc From 02/24/23

The following slide deck was published by Prothena Corporation plc in conjunction with their 2022 Q4 earnings call. For further details see: Prothena Corporation plc 2022 Q4 - Results - Earnings Call Presentation

Prothena Corporation plc (PRTA) Q4 2022 Earnings Conference Call February 23, 2023, 16:30 PM ET Company Participants Eric Endicott - Senior Vice President, Corporate Affairs and Communications Gene Kinney - President and Chief Executive Officer Hideki Garren - Chief Me...

Prothena press release ( NASDAQ: PRTA ): Q4 GAAP EPS of $0.12 beats by $0.61 . Revenue of $49.9M (vs. $1.2M last year) beats by $20.76M . Total revenue for Q4 included a $40M milestone payment from Novo Nordisk ( OTCPK:NONOF ) and revenue for Q4 included BMS collab...

Net cash used in operating and investing activities was $5.1 million in the fourth quarter and $109.3 million for the full year of 2022; quarter-end cash and restricted cash position was $712.6 million Advanced potential best-in-class Alzheimer’s Disease portfolio in 2022: received...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, February 23...

Summary Prothena has several interesting drug candidates for Alzheimer’s, Parkinson’s and two rare diseases. The company has different partnerships, over $3 billion in potential milestone payments, and possibly additional royalties. Wholly owned Birtamimab is a Phase 3...

Prothena Corporation ( NASDAQ: PRTA ) announced Tuesday that PRX005, an Alzheimer's candidate it develops with Bristol Myers Squibb ( NYSE: BMY ), was found to be safe and well tolerated in a Phase 1 trial, meeting the primary objective of the study. In this first-in-human tri...

Results from a single ascending dose (SAD) study in healthy volunteers demonstrated dose-proportional PRX005 concentrations in plasma with robust central nervous system (CNS) penetration of this potentially best-in-class investigational anti-MTBR-tau antibody Single doses of PRX005 across thr...

Piper Sandler has initiated Prothena Corp. ( NASDAQ: PRTA ) with an overweight rating saying that the biotech's platform used to discover antibody therapies and its pipeline will provide share moving catalysts. The firm has a $94 price target (68% upside based on Thursday's close). ...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...